The use of ADCs in conjunction with immune checkpoint inhibitors can sustain an activated immune state within the tumor microenvironment via various immunomodulatory mechanisms, including the reprogramming of macrophages, the generation of T memory cells, the induction of enhanced PD-L1 expression, and the activation of dendritic and T cells. This evidence concerns the gene CD274 and neoplasm.